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ABSTRACT
Periodontitis is characterized by the inflammation of the periodontal tissues in response to
bacterial action. The Global Burden of Disease (GBD) 2010 study shows that periodontitis ranks
6th in the global prevalence of oral health conditions and affects 11% of the world population. It
is initiated by the formation of biofilms containing different types of bacteria. These biofilms
exist as dental plaque and contain three types of bacteria called Tannerella forsythia,
Porphyromonas gingivalis, and Treponema denticola. These three types of bacteria are strongly
associated with periodontitis and they are termed as the Red complex. The main focus of the
research presented herein is on T. forsythia which secrets different types of enzymes that degrade
the periodontal tissues. These enzymes are transcribed and translated together from the genes
clustered together regulated by an operon system. Periodontal tissues are primarily composed of
glycosaminoglycans or (GAGs). These GAGs are linear chains of polysaccharides composed of
different disaccharide units. GAGs can exist in conjunction with proteoglycans which are a
protein core appended with different types of GAGs The degradative enzymes from T. forsythia
degrades the GAGs connected to the protein core, thus contributing to the destabilization and
eventual destruction of the periodontal tissues such as alveolar bone and ligament causing tooth
loss. Based on the bioinformatics and enzyme kinetics, it was found that BFO 2291 (chondroitin
AC lyase) breaks down chondroitin sulfate A into oligosaccharides containing glucuronic acid
and galactosamine. Chondroitin sulfate A is (a type of GAG) one of the main constituents of
many periodontal tissues. Enzyme activity was initially analyzed by doing a pH profile using
various ranges of buffers and pH values. By doing pH profile, we determined the pH at which
this enzyme is the most active which is pH 6.5. Chondroitin AC lyase along with the other
enzymes are responsible for the degradation of chondroitin sulfate A using a GAG degradation
iii
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pathway. The other enzyme analyzed herein was BFO 2294 (KDPG aldolase) which breaks
down

KDPG

(2-keto-3-deoxy-6-phosphogluconate)

aldolase

into

pyruvate

and

D-

glyceraldehyde-3-phosphate. Using a coupled enzymatic assay, it was shown the BFO2294
catalyzed conversion to pyruvate was subsequently converted into lactic acid by lactic
dehydrogenase using cofactor NADH which in turn was oxidized to NAD+. In the last step of
GAG degradation pathway, KDPG is broken down by KDPG aldolase into pyruvate which can
enter into the Krebs cycle and electron transport chain for production of ATP. The final outcome
is the production of ATP which is used by the bacteria to drive its cellular functions. Another
part of our research was structural characterization of BFO2294 via X-ray diffraction analysis.
The BFO2294 enzyme, or KDPG aldolase was successfully crystallized and the diffraction data
was collected. KDPG Aldolase catalyzes the reversible cleavage of 2-keto-3deoxy-6phosphogluconate (KDPG) into pyruvate and D-glyceraldehyde-3-phosphate by retro aldol
cleavage. Using various research articles, it was found that the active site of this enzyme contains
zwitterionic pair of Glu-49 and Lys-141 which are involved in the catalytic reaction between the
enzyme (KDPG aldolase) and the substrate (KDPG).
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1. INTRODUCTION
1.1 What Is Periodontitis?
Periodontitis is characterized by the infection and inflammation of the periodontal tissues that
often leads to alveolar bone loss (1). It is characterized by the inflammation of the periodontal
tissues in response to bacterial infection and initiated by biofilms or dental plaque containing
different types of bacteria (2). The periodontal tissue is made up of different types of
glycosaminoglycans (GAGs) (2). The three pathogens that are also known as the “Red
Complex” (Tannerella forsythia, Porphyromonas gingivalis, and Treponema denticola) are
strongly associated with periodontitis (2). There are several steps that lead to periodontitis which
is shown in figure 1. The first step is the formation of dental plaque which is a biofilm containing
different types of bacteria. In the second step, biofilm is hardened to form tartar or calculus. In
the third step, if the calculus is not treated then gingivitis occurs. Gingivitis is the inflammation
of gingivae. If the gingivitis is not treated, then one is affected by periodontitis. In periodontitis,
a packet develops between the gum and the surface of the tooth. This packet contains different
types of bacteria which destroy the periodontal tissue.
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Plaque

Tartar or
Calculus

Gingivitis

Periodontitis

Figure 1: Steps leading to periodontitis. At first, plaque is formed and if not treated then tartar
builds up. If the tartar is not treated then gingivitis occurs and eventually a more aggressive form
which is periodontitis destroys the gum and teeth.

1.2 Red Complex
The three microorganisms that are known as “Red Complex” are T. forsythia, P. gingivalis, and
T. denticola (3). This complex is the interest of study because it is associated with bleeding on
probing that is an important parameter of destructive periodontal disease (3). According to the
study, 13000 subgingival plaque samples were examined and after that DNA hybridization
methodology and community ordination techniques were used to identify the specific microbial
groups within dental plaque (4). The presence of 40 different subgingival species were
determined using checkerboard DNA-DNA hybridization technique (4). These organisms were
grouped into five complexes according to the presence of an organism and the related
periodontal status which are presented in the figure 2 (4). Among these five groups, yellow,
green and purple complexes precede the multiplication of gram negative red and orange
complexes (4). The red and orange complexes are thought to be the main etiologic agents of the
periodontal disease (4). The bacteria in the “Red Complex” region together produce virulence
factors and in turn initiate an immune response that starts the process of inflammation and the
destruction of periodontal tissues (2). Neutrophils are the white blood cells that are secreted by
2
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the host defense system in inflamed gingival tissues (5). Plaque embedded bacteria and their byproducts could initiate neutrophils recruitment to the area of bacterial invasion in the periodontal
tissues that would result in stimulation of free radical generation (6). Usually, reactive oxygen
species (ROS) produced by phagocytes are used for the killing of the invading pathogens but
prolonged release of ROS and increased matrix metalloproteinases activity cause bone resorption
and degradation of connective tissue surrounding the teeth (6). T. forsythia is a gram-negative
anaerobic bacterium isolated from gingival sulci and periodontal pockets from the patients with
periodontitis (2). T. forsythia contains some putative virulence factors, such as a trypsin-like
protease, a sialidase, hemagglutinin, and a cell surface-associated and secreted protein (BspA)
(7). The protein BspA is considered as a virulence factor that is important for alveolar bone loss
in mice (7). The second bacterium called P. gingivalis produces many virulence factors such as
fimbriae, lipopolysaccharides, and proteases (7). Fimbriae are surface appendages protruding
from the outer membrane of the bacterial cell (8). A study showed that fimbriae have major roles
in the binding as well as invasion of the host cells (8). The lipopolysaccharides are located in the
outer membrane of P. gingivalis and are responsible for the activation of the host inflammatory
response as well as disruption of bone remodeling process (8). This bacterium also secrets
different types of proteases such as trypsin-, thiol-, caseinolytic-proteinases, and peptidases and
they are responsible in destruction of the periodontal tissues (8). Additionally, proteases also
make the microorganisms highly resistant to the host defense system (8). The third bacterium
called T. denticola resembles a small oral spirochete, is frequently found with P. gingivalis in
progressing periodontitis lesions (7).
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Figure 2: Five complexes. According to the presence of an organism and the related periodontal
status, organisms are grouped into five complexes and they are red, orange, yellow, green and
purple. Figure is taken from reference (4).

1.3 Glycosaminoglycans (GAGs)
The extracellular matrix (ECM) underlies all the epithelia, endothelia and surrounds the
connective tissues that provides mechanical and physical support (9). The connective tissues of
periodontium are composed of two soft tissues and they are gingival connective tissues and
periodontal ligament (9). They are also composed of two hard tissues that are alveolar bone and
cementum (9). The connective tissues can be classified into as fibrous (collagens and elastins)
and non-fibrous (proteoglycans) (9). Proteoglycans are generally composed of a core protein
attached with one or more glycosaminoglycans (GAGs) (10). The GAGs chains are linear
polysaccharides composed of repeating disaccharide units that are negatively charged due to the
occurrence of sulfate and carboxyl groups (10). The nature of the GAGs found in periodontal
4

Rony Eshaque

tissues depends on their origin, with heparan sulfate occupying some 60% of gingival
epithelium, dermatan sulfate occupying some 60% of the connective tissue and chondroitin-4sulphate comprising the major GAGs (90%) of alveolar bone (11). The enzymatic degradations
of GAGs involve two enzymes which are hydrolases and lyases (12). The hydrolase cleaves the
glycosidic bond by the addition of the water molecule, whereas the lyase acts by depolymerizing
the GAGs through beta-elimination reaction which is shown in figure 3 (12). The GAG
degrading enzymes depolymerize GAGs through a beta-elimination mechanism characterized by
the removal of a relatively acidic proton from the C5 carbon (the chiral center) of the uronic acid,
and the release of the 4-linked hexosamine with the generation of a C4- C5 double bond at the
uronic acid ring.
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A

B

Figure 3: Degradation of GAGs by two different mechanisms. Panel 1(a) shows eliminative
cleavage using beta-elimination reaction to break down the glycosidic bond. Panel 2(b) shows
hydrolytic cleavage using water molecule to break down the glycosidic bond. Figures are taken
from reference (12).

1.4 Structures of Glycosaminoglycans (GAGs)
GAGs are linear chains of polysaccharides composed of different repeating units of disaccharide
(10). The GAGs are divided into four classes and they are: 1. Heparan sulfate (HS)/Heparin; 2.
Chondroitin sulfate (CS) and Dermatan sulfate (DS); 3. Keratan sulfate (KS); 4. Hyaluronan.

6
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HS/heparin are composed of repeating disaccharide units of hexuronic acid (HexA) and
glucosamine (GlcN). The HexA can be either D-glucuronic acid (GlcA) or L-iduronic acid
(IdoA), and the GlcN residues can be N-acetylated (GlcNAc), N-sulfated (GlcNS) or Nunsubstituted (GlcNH2) (10). CS and DS contain repeating disaccharide units of HexA and Nacetylgalactosamine (GalNAc), CS only contains GlcA, while some of the GlcA can be
epimerized to IdoA in DS (10). Both HexA and GalNAc can be sulfated (10). KS is composed of
alternating partially sulfated galactose (Gal) and GlcNAc residues (10). Hyaluronan is a nonsulfated GAG composed of repeating disaccharide units of GlcA and GlcNAc (10). All the
different types of glycosaminoglycans are presented in the table 1 below and some of the
structures are shown in figure 4.

Figure 4: Structures showing Chondroitin sulfate A and C and Dermatan sulfate. Based on the
positions of the sulfate groups, different types of GAGs are produced. Figures are taken from
reference (12).
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Table 1: Compositions of different types of glycosaminoglycans. Table 1 is showing different
glycosaminoglycans having sulfate groups at varying positions.
Glycosaminoglycans
Chondroitin Sulfate
A
Chondroitin Sulfate
B or Dermatan
Sulfate
Chondroitin Sulfate
C
Heparan Sulfate

Heparin
Keratan Sulfate
Hyaluronan

Disaccharide units
D-Glucuronic acid,
D- Galactosamine
L-iduronic acid, DGalactosamine
D-Glucuronic acid,
D-Galactosamine
D-Glucuronic acid/
L-iduronic acid, Dglucosamine
D-Glucuronic acid/
L-iduronic acid, Dglucosamine
D-galactose, Dglucosamine
D-Glucuronic acid,
D-glucosamine

Sulfate

Sulfate position

O-sulfate

4

O-sulfate

4

O-sulfate

6

N-, O- sulfate

2, 3 and 6

N-, O- sulfate

2, 3 and 6

O-sulfate

6

None

1.5 BFO 2285-2294 GAG -Degrading Operon System
The gene products we are working on are part of an operon system. Operons are groups of
adjacent genes that are each transcribed into a single mRNA (13). These operons usually code
for the genes that are in the same functional pathway (13). They are usually compact and the
genes in the same operon are separated by less than twenty base pairs of DNA (13). Why several
genes are placed in the same operon? The explanation is that the genes placed in the same operon
will have similar expression at the same time together if induced under certain conditions. This
also explains why the operons are believed to contain functionally related genes (13). We are
currently working with two putative GAGs degrading enzymes which are BFO 2291 and 2294
based on bioinformatics analysis. BFO 2291 has putative heparinase II, III, chondroitin AC lyase
and alginate lyse activities, while BFO 2294 is predicted to be similar to the enzyme
KDPG/KHG aldolase. These gene products are predicted to be operated by an operon system and
8
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together they are involved in the degradations of GAGs (Figure 5).

Promoter

Operator

BFO 2288
840 bp

BFO 2289
1140 bp

BFO 2290
1548 bp

BFO 2291
1923 bp

BFO 2292
1038 bp

BFO 2293
789 bp

Figure 5. Putative Operon Structure. The figure is showing the seven gene products in an operon
system which will all be transcribed together by T7 RNA polymerase bound to the promoter
when an inducer binds to the operator.
Table 2: Bioinformatics analysis showing putative functions of the seven gene products
Gene Products
BFO 2288
BFO 2289
BFO 2290
BFO 2291
BFO 2292
BFO 2293
BFO 2294

Putative Functions
4-deoxy-L-threo-5-hexosulose-uronate
ketol-isomerase
Lipoprotein
Arylsulfatase
GAG lyase
Carbohydrate kinase
Gluconate-5-dehydrogenase
KDPG/KHG aldolase

9
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1.6 Significance of Research
The main question that one might ask is why we are conducting research on periodontitis or in
general oral health? The table 3 shows the global prevalence of oral health conditions (14). It
highlights that periodontitis ranks 6th in the global prevalence of oral health conditions and
affects 11% of the world population, while the untreated decay (caries) of permanent teeth ranks
1st in the global prevalence and affects 35% of the world population (14). The treatment options
are currently limited and there is a need for effective treatment for this disease (1). In a healthy
state, the periodontium maintains local tissue homeostasis by balancing its immune response to
the local microbial ecosystem but in a deceased state this homeostasis is broken (1). This process
forces the host immune system to destroy its own tissue, proliferates the pathogenic
microorganisms and also further aggravates the host immune system response (1). This vicious
cycle is the key to periodontitis and the main aim should be to develop therapeutics to break this
cycle and to restore the tissue homeostasis in periodontium (1). Research into characterizing the
following gene products BFO 2291 and BFO 2294 can guide us in understanding the degradation
of periodontal tissues during periodontitis. By initially determining the structure and function of
each enzyme, we can understand how each of the enzymes are involved in the GAGs
degradations during periodontitis. By studying the kinetics of GAGs degrading enzymes, one can
understand the nature of the enzyme and how they behave. By using X-ray crystallography, we
can elucidate the structure of the enzyme which can lead to enzyme-substrate specificity and
based on this we can also develop drugs which can inhibit these enzymes to slow down or halt
the progression of periodontitis.
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Table 3: Global prevalence of oral health Conditions

Conditions
Untreated decay (caries) of
permanent teeth
Severe periodontal (gum)
disease
Untreated caries of
deciduous teeth
Severe tooth loss

World ranking of disease
in prevalence

World Prevalence (%)

1st

35%

6th

11%

10th

9%

36th

2%

2. DEGRADATION OF CHONDROITIN
SULFATE A
Our main hypothesis can be summarized by the figure 6 below. The enzymes identified from T.
forsythia are believed to be responsible for degrading chondroitin sulfate A, one of the main
components of periodontal tissues. Chondroitin sulfate A is broken down by BFO 2291 (GAG
lyase) into disaccharides or oligosaccharides made up of glucuronic acid and N-acetyl
galactosamine linked by glycosidic bond. Then, several other enzymes in the operon further
break down the oligosaccharides into 2-keto-3-deoxy-6-phosphogluconate (KDPG). Then BFO
2294 (Aldolase) acts on (KDPG) to produce pyruvate that enters into Kreb cycle and electron
transport chain for the production of ATP. In conclusion, we can summarize the hypothesis by
saying that T. forsythia produces certain degradative enzymes that are involved in the GAGs
degradation pathway with the production of ATP used to drive its cellular function.

11
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Figure 6. BFO operon system showing different enzymes responsible for the degradation of
Chondroitin Sulfate A. First, Chondroitin Sulfate A is broken down by BFO 2291 into
disaccharides or oligosaccharides made up of glucuronic acid and N-acetyl galactosamine. Down
the road, glucuronic acid is detached from the oligosaccharide by unsaturated hydrolase. This
molecule is further broken down by various enzymes into KDPG which is broken down into Dglyceraldehyde-3-phosphate and pyruvate. Finally, ATP is produced using Krebs cycle and
electron transport chain to drive the cellular functions of the bacteria.

12
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3. METHODS AND MATERIALS
3.1 Bioinformatics and Construct Design
As previously discussed, BFO 2290 and BFO 2294 are part of the operon system which are
suggested via bioinformatics analysis to be involved in GAGs degradation. Using the sequences
provided by National Centre for Biotechnology Information (NCBI), a series of bioinformatics
resources will help to predict the functions and structures of the members of the operon. Some of
the main programs to be used include: Interpro (15), PyMOL (16), Phyre2 (17), STRING-10 (18),
and SignalP (19).

3.2 Construction of Recombinant Plasmids for BFO 2294
The first step of cloning was to design the primers considering any sequence tags. The restriction
enzymes used were NdeI and XhoI. The recognition sequence of NdeI is 5’-CATATG-3’ and
XhoI is 5’-CTCGAG-3’. The overhang used for NdeI is 5’-CTAGCG-3’ and for XhoI is 5’TGCATG-3’.

The

forward

primer

(5’-

CTAGCGCATATGATAAATATGGCAAGATTCGATAAGAAAG-3’) contained recognition
sequence

of

NdeI.

The

reverse

primer

(5’-

TGCATGCTCGAGCTCACGGATAACACCTAATGCC-3’) contained the recognition sequence
of XhoI. These two primers ordered from IDT along with the JumpStart Taq Ready Mix from
sigma were used to construct the gene of interest BFO 2294. The PCR mixtures included 1 μL
of both the forward and reverse primers, 25 μL of JumpStart Taq Ready Mix, 5 μL of genomic
DNA (Tannerella forsythia 92A2 ATCC 43037) and 18 μL of nuclease free water to make up
volume of 50 μL. The construct was amplified by PCR using the annealing temperature of 600 C
and DNA gel electrophoresis was done to check the size of the fragment which was 681 bp. The
13
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pET-21b plasmid was used for the recombinant expression of the gene products (see appendix I).
This plasmid is 5442 base pairs long and encodes for ampicillin resistance. Both the pET-21b
and gene of interest were cut by the restriction enzymes NdeI and XhoI. The mixtures included
25 μL of PCR product or 20 μL of the plasmid, 2.5 μL of NdeI and XhoI, 5 μL of NEB cut smart
buffer and 20 μL or 15 μL of nuclease free water. The mixtures were incubated at 370 C for 1.5
hours and then inactivated at 650 C for 20 minutes. After this process, both the digested PCR
product and the plasmid were cleaned by Qiagen PCR Purification kit. The amplicon was then
inserted between NdeI and XhoI sites in pET-21b plasmid. Then the fragments were joined by
DNA ligase which is termed as ligation. The ligation mixtures included 5 µl of PCR product, 1
µL of plasmid, 1 µL of NEB DNA ligase, 2 µL NEB T4 DNA ligase buffer and 1 µL of nuclease
free water to make up the volume of 10 µL. The mixture was incubated at 40 C for the overnight
and then inactivated at 650 C for 10 minutes. The resulting designated plasmid was termed as
pET-21b-BFO2294.

3.3 Custom Gene for BFO 2291
For BFO 2291, custom gene was ordered from Bio Basic Inc., ligated into pET-28a expression
vector was codon-optimized for expression Escherichia coli. At first, the lyophilized powder was
re-suspended in 40 μL of nuclease free water. This was the original stock. In a new centrifuge
tube, 1:10 dilution of the stock was made with the nuclease free water.

3.4 Transformation and Protein Production
The plasmids (pET-21b) containing the amplicons (BFO 2294) were transformed and plated into
an agar plate. The agar plates were made by mixing 5 grams of Tryptone from Biobasic, 2.5
grams of Yeast extract from Biobasic, 5 grams of NaCl from Bioshop and 7.5 g of Agar A from
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Biobasic with 500 mL of Milli-q water. Ampicillin concentration of 50 μg/mL was used since
the plasmid encodes for ampicillin resistance. The plasmid and amplicon underwent
transformation into a cell line with high efficiency uptake such as the DH5α strain of Escherichia
coli containing many copies of plasmids with the amplicons. The competent cells (DH5α strain
of E. coli) were made competent by treating with calcium chloride. The competent cells were
taken out from the freezer (-800 C) and allowed to thaw in the ice for 10 minutes. After 10
minutes, 1 to 2 μL of the plasmid containing the amplicon were transformed into the competent
cell and allowed to cool in the ice for 30 minutes. For the custom gene (BFO 2291), 2 μL of the
original stock DNA and 2 μL of 1:10 diluted stock DNA were transformed into the competent
cell. After 30 minutes, the cells were heat shocked at 420 C for 42 seconds and allowed to cool in
the ice for 2 to 3 minutes. Then, 200 μL of lysogeny broth (LB) was added to a 1.5 mL microcentrifuge tube containing the competent cell (DH5α strain of E. coli). It was then allowed to
shake in a shaker at 370 C at 240 rpm for an hour. After an hour, the solution was spread in an
agar plate containing the correct antibiotic and incubated in an incubator at 370 C overnight. One
of the single colonies from many colonies were picked and inoculated in liquid media (5 mL)
containing the appropriate antibiotic. The minipreparation using QIAprep Spin Miniprep Kit (50)
was done from DH5α cells and subsequently transformed into BL21 (DE3) strain of E. coli. One
of the single colonies from many colonies were picked and inoculated in liquid media (5 mL)
containing the appropriate antibiotic. Then 5 mL of liquid culture was added to 1 L of LB media
composing of 10 grams of tryptone from Biobasic, 5.0 grams of yeast extract from Biobasic, 10
grams of NaCl from Bioshop. The LB media containg the culture was allowed to shake at 370 C
at 240 rpm until the OD600 reached approximately ~0.6. After reaching the appropriate OD600,
500 μM of 1 mL of isopropyl β-D-1 thiogalactopyranoside (IPTG) was introduced for protein
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induction at 160 C at 160 rpm for overnight. The cells were spin down at 5000 rpm for 8 minutes
at 160 C and the pellets were collected for chemical lysis. The isolation of the protein from the
cells can involve various forms of cell lysis techniques including chemical lysis, sonication, and
French press (20). Chemical lysis involves introduction of 730 mM of 25 mL sucrose solution to
the pellets and stirred until pellets were smooth. Then, 10 mg of lysozyme was added and stirred
for 10 minutes. After this step, 25 mM of 50 mL deoxycholate solution was added and stirred for
10 minutes. The deoxycholate solution included 25 mM deoxycholic Acid, 20 mL of Triton X100 (2% final), 50 mM of 50 mL Tris at pH 7.5, and 300 mM NaCl to make up a 1 L of solution.
The lysozyme, deoxycholate and Triton X-100 were used to disrupt the cell walls and
deoxycholate is effective in disrupting and dissociating many types of protein interaction. After
this stage, 375 μL of MgCl2 and 75 μL of DNase were added. The addition of DNase is
responsible for cleaving up single-stranded and double-stranded DNA to decrease viscosity from
the chemical lysate (21). DNase solution contained 666 μg/mL DNase from Biobasic, 6 mL of
100% glycerol and 4 mL distilled water to make up to 30 mL of solution. At this stage, the
solution should be smooth. The solution was spun down at 15000xg at 40 C for 35 minutes and
the supernatant was collected.

3.5 IMAC, Anion Exchange Chromatography and Dialysis
Immobilized metal affinity chromatography (IMAC) followed chemical lysis which is a method
to purify recombinant protein with a short affinity tag consisting of polyhistidine residues. IMAC
is based on the interaction between a metal ion (Cu2+, Ni2+ and Co2+) and specific amino acids
which is histidine in this case (22). Subsequently, nickel nitrilotriacetic acid (Ni-NTA) agarose
was used in order to purify the protein which was bought from ThermoFisher Scientific. Ni-NTA
agarose uses nitrilotriacetic acid (NTA), a chelating ligand that binds the Ni2+ ions coupled to a
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solid support resin usually agarose (23). The supernatant was loaded on Ni2+ ions coupled to a
solid support resin (6% crosslinked agarose) and allowed to equilibrate on a rocker for 1 hour at
40 C. At first, flow through was collected and then using wash buffer (5 mM imidazole, 300 mM
NaCl and 50 mM Tris-HCl), low affinity bound proteins were removed. The elution buffer
contained 50 mM Tris-HCl, 300 mM NaCl and 500 mM imidazole. Using imidazole gradient at
constant pH 8, different fractions were collected. The imidazole gradient used were 5 mM, 25
mM, 50 mM, 75 mM, 100 mM, 125 mM, 150 mM, 175 mM, 200 mM, 225 mM and 250 mM
Imidazole and the samples were run on SDS gel. All of the protein fractions were pooled
together and were prepared for dialysis for buffer exchange using Fisherbrand dialysis tubing
(50mm in width). For BFO 2291, the dialysis tube containing the protein was buffer exchanged
in 20 mM sodium phosphate buffer at pH 7.8 for 1 hour and then it was switched into fresh 20
mM sodium phosphate buffer at pH 7.8 for overnight buffer exchange. For BFO 2294, the
dialysis tube containing the protein was buffer exchanged in 50 mM Tris-HCl buffer at pH 8 for
1 hour and then it was switched into fresh 50 mM Tris-HCl buffer at pH 8 for overnight buffer
exchange.
Further purification was done using an anion exchange chromatography where anion
exchanger was used to remove the contaminants (24). For BFO 2294, the buffer used was 50
mM Tris-HCl at pH 8 and for the protein BFO 2291, the buffer used was 20 mM sodium
phosphate at pH 7.8 because this protein is soluble in the sodium phosphate buffer. The
concentration of salt used to elute the protein bound to the column was 1 M NaCl. After this step,
the protein was concentrated using Amicon Ultra-15 centricons in a centrifuge at 40 C until the
desired protein concentration was achieved. The centricons have a filter with a cut-off limit (10
kDa) and particles such as salt or smaller proteins that fall below the limit will flow through,
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while the proteins above the limit (including the expressed protein of interest) will collect above
the filter and concentrate to a lower volume (25). Before working with the purified protein, the
concentration of the protein must be determined. The reading of protein concentration was
achieved using a Thermo Scientific Genesys 10S UV-VIS Spectrophotometer to scan the
absorbance from 300nm to 250nm. Rather than reading from only 280nm to indicate the
presence of aromatic rings in protein structure, a range can depict peak broadening or if
contamination is present at wavelengths not expected to read for protein. The absorbance values
at 280nm would apply to Beer’s Law to calculate protein concentration given the path length of
the cuvette and extinction coefficient. The extinction coefficient for BFO 2291 was estimated via
ProtParam to be 140525 M-1 cm-1 and BFO 2294 was 28585 M-1 cm-1.

3.6 Substrate Specificity For BFO 2291
Different substrates were tested for substrate specificity for the enzyme BFO 2291 (GAG lyase).
Heparan sulfate as well as various types of chondroitin sulfate (chondroitin sulfate A,
chondroitin sulfate B and shark chondroitin sulfate) were tested spectrophotometrically for the
activity. The buffer used was 50 mM sodium phosphate at pH 6.5. A constant amount of each
substrate (1 mg/mL) and 50 μg/mL of the enzyme were taken and lyase activity was measured
based on the increase in absorbance by the double bond containing glucuronic acid at 232 nm at
room temperature. (See figure 1A) (26).

3.7 pH Profile For BFO 2291
Different buffers were used for determining the optimum pH that gave the maximum enzymatic
activity. For the enzyme, BFO 2291 (GAG lyase), different buffers at different pH were used in
order to establish the maximum enzymatic activity. The enzyme was concentrated to 50 μg/mL.
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The substrate used was chondroitin sulfate A and the concentration used was 1 mg/mL. The
different buffers at 50 mM concentration were used. The buffers used were sodium phosphate at
pH 6.5, 7.0, 7.5 and 8.0, Glycine-NaOH at pH 9.0 and 9.5, Hepes-NaOH at pH 7.0 and 7.5, TrisHCl at pH 7.5, 8.0 and 8.5, Pipes-NaOH at pH 6.0 and 6.5, Sodium Citrate-NaOH at pH 4.5, 5.0
and 5.5 and Sodium Acetate-NaOH at pH 4.0 and 4.5.

3.8 Enzyme Kinetics For BFO 2291
The kinetic analysis of GAG lyase (BFO 2291) was done spectrophotometrically using the
substrate chondroitin sulfate A. The GAG lyase activity was measured based on the increase in
absorbance at 232 nm of the double bond containing glucuronic acid (Product) (26). A stock
solution of 3 mg/ml of chondroitin sulfate A was prepared by dissolving 30 mg/ml of chondroitin
sulfate A in 10 mL of 50 mM sodium phosphate buffer at pH 6.5. A range of concentrations were
used ranging from 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.5 mg/mL, 0.7 mg/mL, 1.0 mg/mL, 1.5
mg/mL, 2.0 mg/mL, 2.5 mg/mL. The enzyme concentration was 50 μg/mL. The total volume of
the solution was 1 mL and they were added to a quartz cuvette with 1 cm path length. The
absorbance readings were recorded for one minute at 232 nm for each of the concentration at
room temperature. Each reaction was done in triplicates. The molar extinction coefficient, ε, of
double bond containing glucuronic acid used was 3800 M-1 cm-1 to determine how much product
was formed in µM/min (26).

3.9 Enzyme Kinetics for BFO 2294
BFO 2294 (Aldolase) activity was measured using coupled assay with L-lactic dehydrogenase.
The reagents used were 50 mM Hepes buffer at pH 7.0, 6mM NADH, 500 mM stock
concentration

of

the

substrate

2-keto-3-deoxy-6-phosphogluconate

(KDPG),

L-lactic
19

Rony Eshaque

dehydrogenase from rabbit muscle: Type II, ammonium sulfate suspension, 800-1,200 units/mg
protein and they were added to a quartz cuvette with 1 cm path length (27). The total volume of
the solution was 1 mL and different concentrations of the substrate were used (100 mM, 120
mM, 130 mM, 140 mM, 150 mM and 160 mM). The enzyme aldolase (50 μg/mL) was added
last to initiate the reaction and the disappearance of NADH was monitored for an interval of 1
minute by observing the decrease in absorbance at 340 nm at room temperature (27). The molar
extinction coefficient of NADH used was 6220 M-1 cm-1 (27). The enzymatic activity of aldolase
was also checked by negative controls such as not adding aldolase or LDH at room temperature.

3.10 X-ray Crystallography
Commercially available sparse-matrix conditions were screened for positive crystallization
conditions which require a wide selection of buffers, precipitating agents and additives with
varying conditions including pH, temperature, and concentration. Vapour diffusion method can
be performed in either the sitting-drop or hanging-drop format and both are feasible techniques
that can be prepared in 24 or 96-well plates (28). Some suggested pre-made crystallization
screens that may be used for from Microlytic Anatrace MCSG-1-4 crystal screen HT (1.7mL),
Hampton Research Index Solution Set 1 reagents 1-48 HR2-144 and Solution Set 2 reagents 4996 HR-144. The protein BFO 2294 was dialyzed in 50 mM Tris-HCl buffer at pH 8.0. The
protein was concentrated using Amicon Ultra-15 centricons in a centrifuge at 40 C until the
desired protein concentration (14 mg/mL) was achieved. For the protein BFO 2294, an
expansion plate was set up (24 wells) using different reagents at varying concentration including
40 M of Tacsimate (TM) at pH 7.0 and 11 M of Tacsimate (TM) at pH 9.0 from Hampton, 0.75
M to 6.25 M of glycerol at pH 8.2 as reservoir solution. Tacsimate is a unique crystallization
reagent developed exclusively by Hampton Research. Tacsimate is composed of a mixture of
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titrated organic acid salts. Tacsimate contains 1.8305 M Malonic acid, 0.25 M Ammonium
citrate tribasic, 0.12 M Succinic acid, 0.3 M DL-Malic acid, 0.4 M Sodium acetate trihydrate, 0.5
M Sodium formate, and 0.16 M Ammonium tartrate dibasic. This mixture is titrated to the
appropriate pH using sodium hydroxide and is available in pH 4, 5, 6, 7, 8, or 9 reagent
formulations. The crystals were grown in the condition containing 6.25 M of glycerol, 400 μl or
40 M of Tacsimate 7.0 and 106 μl or 11 M of 9.0 at pH 8.2 as reservoir solution. Then a plastic
coverslip was used where different ratios of reservoir solution (1-2 μL) and protein (2-3 μL) was
mixed. The final concentration of the protein was 14 mg/mL. Then the crystal plate was kept in
the incubator at 160 C. After three weeks, the crystals were obtained and the shapes of the
crystals were cubic. The sizes of the crystals were approximately 0.4 μm and the cryoprotectant
used to soak the crystals was 30% Tacsimate 7.0 and 9.0. For the protein BFO 2291, 96 well
plate was set up using 200 mM of imidazole as reservoir solution. The protein BFO 2291 was
dialyzed in 20 mM phosphate buffer at pH 7.8. Then a plastic coverslip was used where different
ratios of reservoir solution (1-2 μL) and protein (2-3 μL) was mixed. The final concentration of
the protein was 19 mg/mL. Then the crystal plate was kept in at room temperature. After one
day, the crystals were obtained and the shapes of the crystals were cubic. The sizes of the
crystals were approximately 60 μm and the cryoprotectant used to soak the crystals was 30%
ethylene glycol. All the crystals were sent to The Canadian Light Source for X-ray diffraction
data collection and analysis (29).
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4. RESULTS And DISCUSSION
4.1 Bioinformatics Analyses
The first step was to do bioinformatics analyses of the gene products in order to find out the
putative functional characteristics. STRING-10 provides a visual representation and interactive
map of associated proteins (Figure 7) with protein-protein interactions surrounding the target
protein thus leading to the understanding of the pathways within the species’ genome (30). To
figure out more specific details about the targeted sequence, InterPro is useful for predicting
domains and important sequence-based features (Figure 8) that might be present (31). InterPro is
classified as a database of protein families, domains and functional sites in which known features
found in known proteins can be applied to new protein sequences in order to functionally
characterize the new protein (15)
Additionally, Phyre2 can help determine potential truncation sites when designing
primers for recombinant proteins by comparing the structure of similar proteins based on
sequence homology (32). SignalP 4.1 is another useful bioinformatics tool that predicts whether
the input sequence possesses a signal peptide (Figure 9) for cellular targeting (33). This tool is
useful when cloning certain genes by cleaving the signal peptide.
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Figure 7: Interactive map and predicted functional partners of BFO 2294 provided by STRING10. Other associated proteins selected for the project based off this bioinformatics tool are BFO
2292 and BFO 3308 (30). It suggests that BFO 2292 and BFO 3308 are in the same pathway as
BFO 2294 and they are involved in the metabolism of carbohydrate.
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Figure 8: InterPro results for BFO 2294 suggest signature matches to a KDPG/KHG aldolase
domain eluding to a TIM barrel structure. BFO 2294 corresponds to the KDPG/KHG aldolase
family (31).

Figure 9: SignalP 4.1 graph displaying signal peptide scores to distinguish predicted localization
of BFO 2294 as a putative secretory protein. C-score (red) represents the raw cleavage site score;
S-score (green) represents the signal peptide score; and Y-score (blue) represents the combined
effects of the C- and S- scores for a more accurate predicted cleavage site. In the case of BFO
2294, no signal peptide exists because it is targeted towards bacterial cytoplasm.
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4.2 IMAC and Protein Purification
Immobilized metal affinity chromatography (IMAC) was used to purify the recombinant proteins
BFO 2291 and 2294. IMAC utilizes the interaction between a transition metal ion Ni2+
immobilized on a matrix and a specific amino acid called histidine (22). Histidine forms the
strongest interaction with immobilized matrix because electron donor group on the histidine
imidazole ring form coordination bond with immobilized transition metal (22). Affinity tags
consisting of six polyhistidine residues are commonly used in IMAC and they can be
incorporated either at the N or C terminus of the recombinant protein (22). The gene encoding
the polyhistidine tag was incorporated in the N terminus of the pET-28a and pET-21b plasmids
(22). There are various immobilized metal matrices available for use in IMAC and the choices
include iminodiacetic acid (IDA) or nitrilotriacetic acid (NTA) as metal ligands (22). The
problem with IDA is that it can bind metal ion by three-coordination sites (22). Hence, the metal
ions bind weakly to that three-coordination matrix resulting in metal leaching which causes
lower yields and impure products (22). In our case, Ni-NTA was used because it can bind Ni2+
ions by four-coordination sites, leaving two of the transition metal coordination sites free to
interact with the histidine residues (22). As described in the Methods and Materials, wash buffer
(50 mM Tris, 300mM NaCl and 5mM imidazole, pH 8.0) was used to wash away any nonspecific associated protein and the protein of interest with polyhistidine tag will be tightly bound
to the Ni-NTA beads (22). The tagged protein usually has higher binding affinity to the resin
than other non-specific bound proteins (22). Thus, it is recommended to use the minimum
amount of resin so that the tagged protein will fill most of the available binding sites in process
reducing the binding of non-specific bound proteins (22). Proteins can be released from the
complexes by reducing the affinity constant between the immobilized metal ion and the tagged
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protein (34). There are different methods such as change in the salt concentration, pH and
displacing by a competitive agent (imidazole) which resembles the histidine residues that can be
employed (34). In our case, different concentrations of imidazole were used to displace the
bound polyhistidine tagged protein from the complex. The figure 10 shows the elution of BFO
2294 using a step gradient of 50 mM, 75 mM, 100 mM, 125 mM, 150 mM, 175 mM, 200 mM,
225 mM, 250 mM and 260 mM imidazole. The predicted molecular weight of this protein is
around 24 kDa. The gel looks poor, potentially because of the elution buffer not being fresh.
Then the fractions containing the proteins were pooled (75 mM to 250 mM) and dialyzed in a
buffer to exchange salts and imidazole. In Biochemistry, dialysis is a simple technique for
separating molecules in solution by diffusion (35). Diffusion is a process by which atoms, ions or
molecules move from an area where they are high in concentration to the area where they are
low in concentration (35). A semipermeable membrane, in this case the dialysis tubing only
allows particles smaller than a certain size to pass through it which are salts, imidazole and other
contaminants. Thus, the protein of interest will be retained in the dialysis tubing. During dialysis
in a buffer (dialysate), some of the salts and imidazole will move out from the area of high
concentration (dialysis tubing) to the area of low concentration (dialysate) until an equilibrium is
established. After 1 hour, concentrations of the salts and imidazole in the sample protein will be
reduced to a significant amount. When we replace the old buffer with the fresh new buffer,
another equilibrium will be established between the sample and dialysate in the process further
reducing the concentrations of the salts and imidazole in the sample. The basic idea of dialysis is
to reduce the concentrations of the salt and imidazole from the protein sample which can
otherwise impede the process of crystallization. The next step was to further purify the protein
sample using ion exchange chromatography (36). Ion exchange chromatography is a common
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technique for separating charged molecules such as proteins, peptides, amino acids and
nucleotides (36). Proteins are made up of amino acids that contain both positively charged and
negatively charged chemical groups. Proteins may carry a net positive charge, a net negative
charge or no charge. The pH at which proteins have no net charge is called its isoelectric point or
pI. A protein will carry a net negative charge in a buffer with pH greater than pI and therefore an
anion exchange resin (positively charged) will be used for binding the protein. A protein will
carry a net positive charge in a buffer with pH lower than pI and therefore a cation exchange
resin (negatively charged) will be used for binding the protein. Anion exchange chromatography
was performed to remove any other protein contaminants that may impede crystallography. The
figure 14 shows protein band for BFO 2291 at 74 from different tubes containing the protein
fraction. We can see the protein looks very pure after anion exchange chromatography. Anion
exchange instead of cation exchange was performed for BFO 2294 because the theoretical
isoelectric point (pI) of this protein is 5.57 and the buffer used was 50 mM Tris-HCl at pH 8.0.
This makes the overall charge of the protein (BFO 2294) negative. Anion exchange was also
performed for BFO 2291 because the theoretical isoelectric point (pI) of this protein is 6.44 and
the buffer used was 20 mM sodium phosphate buffer at pH 7.8. This makes the overall charge of
the protein (BFO 2291) negative. Anion exchange chromatogram for BFO 2291 and BFO 2294
are shown in figure 12 and 13. The SDS gel is shown in figure 14 that shows purified protein
(BFO 2291) after anion exchange chromatography.
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Figure 10: BFO 2294 IMAC Purification run at 200 V for 40 min. 12% (w/v) SDS PAGE
analysis of protein fractions during Ni-NTA IMAC purification. Column 1 to 11 represent as
follows: Flow through (FT), 50 mM imidazole, 75 mM imidazole, 100 mM imidazole, 125 mM
imidazole, 150 mM imidazole, 175 mM imidazole, 200 mM imidazole, 225 mM imidazole, 250
mM imidazole and 260 mM imidazole. BFO 2294 which is predicted to be 24 kDa can be seen
close to 25 kDa on the ladder band. Protein elutes strongly above 125 mM imidazole.
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Figure 11: BFO 2291 IMAC Purification run at 200 V for 40 min. 12% (w/v) SDS PAGE
analysis of protein fractions during Ni-NTA IMAC purification. Column 1 to 12 represent as
follows: Flow through (FT), 5 mM imidazole, 25 mM imidazole, 50 mM imidazole, 75 mM
imidazole, 100 mM imidazole, 125 mM imidazole, 150 mM imidazole, 175 mM imidazole, 200
mM imidazole. 225 mM imidazole and 250 mM imidazole. BFO 2291 which is predicted to be
74 kDa can be seen close to 75 kDa on the ladder band. Protein elutes strongly above 50 mM
imidazole.

29

Absorbance (mAU)

Rony Eshaque

Retention Time (min)

Figure 12: Anion exchange chromatogram for BFO 2291. This chromatogram shows a single
large curve starting from about 150 mAU reaching the peak at about 400 mAU at 280 nm. The
retention time of the peak is around 170 min. The protein starts to elute at about 375 mM of
NaCl and is completely eluted by the time 200 min. The elution buffer used was 20 mM sodium
phosphate, 1 M NaCl at pH 7.8
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Figure 13: Anion exchange chromatogram for BFO 2294. This chromatogram shows a single
curve starting from about 100 mAU reaching the peak at about 310 mAU at 280 nm. The
retention time of the peak is about 183 min. The protein starts to elute at about 83 mM of NaCl
and is completely eluted by the time 220 min. The elution buffer used was 50 mM Tris-HCl, 1 M
NaCl at pH 8.0.
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Figure 14: Anion exchange of BFO 2291. Purified protein collected from different tubes
numbered 12 to 28 (during FPLC) and corresponds to the retention time between 150 min to 190
min. The protein starts to elute at about 375 mM of NaCl

4.3 Substrate specificity for BFO 2291
Based on bioinformatics analyses, BFO 2291 (GAG lyase) belongs to heparinase II/III like
protein family (see appendix II). This protein was suggested to have a domain containing
chondroitin AC/Alginate lyase activity. We eliminated alginate lyase based on the fact that
alginate is not a glycosaminoglycans. Based on this information, we did some initial kinetics in
order to establish the enzyme substrate relationship. If we look at figure 35 in appendix III, we
can see that there is a small indication of increase in absorbance at 232 nm. By using the molar
extinction coefficient 3800 M-1 cm-1, we calculated the amount of product formed to be 0.68
µM/min (26). For figure 36 in appendix III, there is a decrease in absorbance and that is not what
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we should have seen if lyase activity was detected. It gave us a negative slope. Lastly, for figure
37 in appendix III, we observe some activity as well with shark chondroitin sulfate. In theory, it
should show some activity because shark chondroitin sulfate contains all the mixture of
chondroitin sulfate A, B and C. We calculated the amount of product formed to be 0.26 µM/min.
The table 4 shows amount of product formed for different types of chondroitin sulfates. We can
use these data as a pilot study since, the increase in absorbance for the substrate chondroitin
sulfate A is not highly significant. Based on the analysis, we can summarize the results saying
that chondroitin sulfate A is the best substrate for the enzyme BFO 2294 which is predicted to be
chondroitin AC lyase based on bioinformatics. The table 5 shows the amount of product formed
in the presence and absence of the enzyme. We can see that the products are increased in the
presence of the enzyme showing the enzyme is required for the product formation.
Table 4: Amounts of products formed for different types of chondroitin sulfates by BFO 2291
Compounds
Chondroitin Sulfate A
Chondroitin Sulfate B
Shark Chondroitin

Amount of Product Formed (µM/min)
0.68
-1.1
0.26

Table 5: Amounts of products formed for different types of chondroitin sulfates in the absence
or presence of BFO 2291
Compounds
Chondroitin Sulfate A
Shark Chondroitin

Amount of Product Formed
(µM/min) without BFO 2291
0.13
0.16

Amount of Product Formed
(µM/min) with BFO 2291
6.5
5.0

4.4 pH profile for enzymatic activity for BFO 2291
The pH-optimum means the pH at which enzymatic activity is maximal (37). There are many
macromolecular properties such as activity and protein stability that depend on pH. The pH is
very important when it comes to enzymatic activity (38). Pepsin, one of the digestive enzymes
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that breaks down protein molecules is highly active at pH 2.0-3.0 (39). Most of the dental
bacteria live in an acidic condition (40). The pH of the oral cavity is around 7 but during
periodontitis, the pH gets more acidic (40). It means that most of the enzymes produced by
dental bacteria are more active in acidic pH. The extremely high or low pH can cause complete
loss of the enzyme activity (37). The pH dependence of activity and stability usually resemble a
typical bell-shaped curve with a single or several maxima and the maximum (maxima) is called
pH-optimum (38). Such curves reflect the ionization of certain amino residues that must be in
certain ionization state for enzymatic activity (41). Most enzymes are active within a narrow pH
range from 5 to 9 (41). This phenomenon is an effect of pH on a combination of factors and they
are binding of the substrate to an enzyme, the ionization of the substrate, the ionization states of
the amino acid residues involved in the catalytic activity of the enzyme (41). In figure 15, we can
see the pH-optimum is established. Based on the graph, we can conclude that sodium phosphate
and pipes have the maximum activity at pH 6.5 but phosphate buffer was chosen as the buffer of
choice because this specific protein was soluble in phosphate buffer. Before establishing the pH
profile for this protein, we were doing the kinetics in phosphate buffer at pH 7.6 but after
establishing the pH profile, we are able to study kinetics under optimal conditions. We also
showed one of the rate curves (see figure 16) used to generate the figure 15.
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Figure 15: pH profile for BFO 2291. The curve shows the effects on reaction rate at different pH
range. The enzyme concentration was 50 μg/mL, the substrate concentration of chondroitin
sulfate A was 1 mg/mL and the concentrations of all the buffers were 50 mM.
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Figure 16: Rate curves for phosphate buffer at pH 7.0. One of the rate curves used to generate
the figure 15. The enzyme concentration was 50 μg/mL, the substrate concentration of
chondroitin sulfate A was 1 mg/mL and the concentrations of all the buffers were 50 mM.

4.5 Enzyme Kinetics for BFO 2291
The primary function of an enzyme is to increase the rate of reactions so they are compatible
with the needs of the organism (42). In order to understand the function of an enzyme, we need a
kinetic description of an enzyme activity (42). For most of the enzymes, initial reaction velocity
(V0) varies with substrate concentration [S]. The initial reaction velocity increases linearly as the
substrate concentration increases and begins to reach a plateau at higher substrate concentration
(42). The plateau occurs because all available enzymes are occupied by the substrate molecules
and additional substrate molecules can only bind the enzyme when enzyme becomes available
for binding. In Figure 17, the initial reaction velocity (V0) is plotted against substrate
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concentration [S] for BFO 2291. We are measuring the initial rate of reaction (V0) right after
adding the enzyme to the substrate at specific concentration because the reaction will slow down
to zero as all the substrates are used up. The same concentration of enzyme was used for each
reaction so that we keep the enzyme concentration constant and only changing around the
substrate concentration. Each reaction was done in triplicates so that we have a reproducible
data. After a certain substrate concentration, the graph levels off to a plateau as expected. The
figure 18 shows smoothed curve with experimental values with error bars.
In order to analyze the kinetics data, we need to be familiarized with certain terms. The
maximum velocity or Vmax is the theoretical maximum value for V0 and Michaelis constant KM is
the concentration of [S] producing a V0 of Vmax/2. The equation that accounts for the kinetic data
shown in table 2 is called Michaelis-Menten equation. The equation is V0 = Vmax [S]/KM+[S].
When the substrate concentration is very low, [S] is much lower than KM, V0 = (Vmax/KM) [S]. It
means the rate is directly proportional the substrate concentration. When the substrate
concentration is very high, [S] is much higher than KM, V0 = Vmax. It means the rate is at
maximum, independent of the substrate concentration. If we look at the Michaelis-Menten
equation, we can say that V0 = 1/2Vmax when KM = [S]. Thus, we can conclude that KM = [S] at
which reaction rate is half of it maximum value. For most of the enzymes, KM lies between 10-1
to 10-7 M. The question is what is defined by the KM of an enzyme? The Michaelis constant gives
us the concentration at which half of the active site of an enzyme is filled by the substrate. By
using the value of KM, we can calculate the fraction of active sites (fES) filled at any substrate
concentration using the following equation: fES = [S]/[S]+KM. We can also make some
assumptions about the strength of enzyme-substrate [ES] complex based on the KM values. The
enzyme-substrate complex is the intermediate step when enzyme binds with specific substrate in
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order to produce the product. If the KM value is large, then we can say the binding of enzymesubstrate complex is weak and if the KM value is small, then then we can say the binding of
enzyme-substrate complex is strong. If that is true, then we can say a low KM value also means
that the enzyme requires only small amount of substrate to become saturated. In this case, the
Vmax will reach at low substrate concentration. If the KM value is large, then we can say the
enzyme requires higher amount of substrate to reach the Vmax. We can also conclude saying that
Vmax reveals the turnover number of an enzyme and that is the number of substrate molecules
converted into product by an enzyme molecule in a unit time when the enzyme is fully saturated
with substrate. It is also equal to kinetic constant k2 or kcat can be calculated when the enzyme is
fully saturated with the substrate molecule. The Vmax reveals the turnover number of the
particular enzyme if the concentration of the active site [E] t is known. The equation can be
written as Vmax = k2[E]t and can be rearranged as k2 = Vmax/[E]t. For most of the enzymes, the
values of KM lie between 10-1 to 10-7 M (42). All of the kinetic parameters were calculated via
non- linear regression. By analyzing the KM value of BFO 2291, we can explain the behaviour of
this enzyme. As we previously discussed, low KM value means that the enzyme requires only
small amount of substrate to become saturated, while high KM value means the enzyme requires
higher amount of substrate to become saturated. In the case of BFO 2291, the KM value of BFO
2291 is 396 μg/mL. The table 7 gives KM value for Chondroitin AC lyase from B. stercoris
which is 388 μg/mL. If we compare the KM value of Chondroitin AC lyase from Bacteroides
stercoris and the KM value of BFO 2291, we can conclude that the values of both enzymes are
very close indicating nature of BFO 2291 is very similar to Chondroitin AC lyase. By examining
the Table 4, we can see the value of kcat is 1.55/sec. The value of kcat reveals the turnover number
which is defined as the maximum number of substrate molecules per unit time that get converted
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by a single catalytic site at a given enzyme concentration. The turnover numbers of most
enzymes with their corresponding substrates fall in the range from 1 to 104 per second (42).
When the concentration of the substrate is much greater than KM, the rate of reaction is equal to
kcat but most enzyme are not saturated with their corresponding substrates (42). When [S]<< KM,
the rate of reaction is much less than kcat because most of the active sites are unoccupied (42).
The value of kcat/KM is helpful in determining substrate specificity, catalytic efficiency and
kinetic perfection (42). The rate constant for association of E+S is k1 which sets an upper limit
value for kcat/KM. How fast two molecules can bind (enzyme and substrate) is limited by how fast
the two molecules can diffuse (bump into each other) so they can react (42). Thus, the maximum
value of kcat/KM for an enzyme is 108-109 M-1Sec-1 (42). An enzyme with the kcat/KM value in that
range approaches the diffusion control limit and approaches kinetic perfection (42). It means the
rate at which the enzyme’s active site can convert substrate into product is limited only by the
rate at which it encounters the substrate in solution (42). The higher the value of kcat/KM for an
enzyme, the more efficient an enzyme is. It also means that enzyme works better on that
particular substrate. The Vmax of BFO 2291 is 62.0+/- 2.8 μM/min and the Vmax of Chondroitin
AC lyase from B. stercoris is 76.7+/-1.5 μM/min. This again indicates that the values of Vmax are
very close. By comparing the values of BFO 2291 with the Chondroitin AC lyase from B.
stercoris tells us that the efficiency and nature of the two enzymes are very similar. The figure 18
shows the smoothed curve which is generated by applying the values in the equation V0 = Vmax
[S]/KM+[S].
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Figure 17: BFO 2291 Enzyme Kinetics. The figure shows the relationship between the increase
in concentration of the chondroitin sulfate A[S] and the initial reaction velocity (V0). The values
for KM, kcat, and Vmax were found using the online software called IC50 tool kit.
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Figure 18: BFO 2291 Enzyme Kinetics. This figure shows smoothed curve with experimental
values with error bars and the values for KM, kcat, and Vmax were found using the online software
called IC50 tool kit.
Table 6: Kinetic parameters of BFO 2291 and the substrate is chondroitin sulfate A
KM (μg/mL)

kcat (sec−1)

Vmax (μM/min)

396

1.55

62.0+/- 2.8

kcat/ KM (mg/ml-1.
sec-1)
3.92

Table 7: Kinetic parameters of Chondroitin AC lyase from Bacteroides stercoris taken from (43)
Substrate
Chondroitin Sulfate A

Vmax (μM/min)
76.7+/-1.5

KM (μg/mL)
388
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4.6 Enzyme Kinetics for BFO 2294
To measure the activity of BFO 2294 (Aldolase), we had to perform a coupled assay. According
to figure 6, aldolase converts the substrate KDPG into pyruvate and D-glyceraldehyde-3phosphate. The pyruvate is converted to lactic acid by lactic dehydrogenase using cofactor
NADH which in turn gets oxidized to NAD+. We are measuring the amount of NADH being
converted to NAD+ at 340 nm. The full reaction equation is shown in figure 19. The enzymatic
activity was also tested by using different types of negative controls. This was done just to
confirm whether any other factors are contributing to the activity that is seen in figure 23. The
figure 20 shows there is no specific activity if the aldolase is not added in the mixture. In the
figure 21, there is no activity without the aldolase and LDH and also in figure 22, there is no
activity if the LDH is not added as well. In figure 23, there is a clear trend if both the aldolase
and LDH are added. It proves that both the enzymes are needed in order to see the aldolase
activity. If we look at the figure 37 in appendix IV, we can see that we only took single reading
for each concentration because we just wanted to test whether the enzyme has aldolase activity
or not. The data in figure 37 in appendix IV is inconclusive and needs further study to establish
the kinetics. The table 8 shows amount of product being formed for different types of controls.
Based on this table, we can say that maximum amount of product is being formed when KDPG,
Aldolase and LDH are mixed together.
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Figure 19: KDPG aldolase is broken down by BFO 2294 into pyruvate. Pyruvate is converted
into lactic acid using LDH and a cofactor NADH which in turn gets oxidized into NAD+. The
disappearance of NADH is measured at 340 nm.
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Figure 20: KDPG plus LDH. This figure shows there was no specific activity if the aldolase is
not added in the mixture. The buffer used was 50 mM Hepes-NaOH at pH 7.0, 500 mM stock
concentration

of

the

substrate

2-keto-3-deoxy-6-phosphogluconate

(KDPG),

L-lactic

dehydrogenase from rabbit muscle: Type II, ammonium sulfate suspension, 800-1,200 units/mg
protein

44

Rony Eshaque

Absorbance (340 nm)

y = -0.00130x + 1.72
R2

1.726
1.724
1.722
1.72
1.718
1.716
1.714
1.712
1.71
1.708
1.706
0

0.2

0.4

0.6

0.8

= 0.0225

1

1.2

Time (min)

Figure 21: KDPG without LDH And Aldolase. This figure shows there was no specific activity
if the LDH and aldolase are not added in the mixture. The buffer used was 50 mM Hepes at pH
7.0, and 500 mM stock concentration of the substrate 2-keto-3-deoxy-6-phosphogluconate
(KDPG) was used.
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Figure 22: KDPG plus Aldolase. This figure shows there was no specific activity if the LDH is
not added in the mixture. The buffer used was 50 mM Hepes at pH 7.0, 500 mM stock
concentration of the substrate 2-keto-3-deoxy-6-phosphogluconate (KDPG), and the enzyme
concentration was 50 μg/mL.

46

Rony Eshaque

y = -0.103x - 0.332
R² = 0.913
0

Absorbsnce (340 nm)

-0.05 0

0.2

0.4

0.6

0.8

1

1.2

-0.1
-0.15
-0.2
-0.25
-0.3
-0.35
-0.4
-0.45
-0.5

Time (min)

Figure 23: KDPG, Aldolase and LDH. This figure shows there was an activity if both the
aldolase and LDH are added in the mixture. The buffer used was 50 mM Hepes at pH 7.0, 500
mM stock concentration of the substrate 2-keto-3-deoxy-6-phosphogluconate (KDPG), the
enzyme concentration was 50 μg/mL, and L-lactic dehydrogenase from rabbit muscle: Type II,
ammonium sulfate suspension, 800-1,200 units/mg protein
Table 8: Amount of product formed for different types of controls
Controls
KDPG and LDH onl
KDPG without LDH and Aldolase
KDPG plus Aldolase
KDPG, Aldolase and LDH

Amount of Product Formed (µM/min)
0.370
0.209
0.193
16.7
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4.7 Principles of Protein Crystallization
X-ray crystallography is the most convenient method for determining the structure of a purified
protein in crystal form (29). Protein crystallization was discovered by accident about 150 years
ago and was developed as a purification tool in the late 19th century (44). The aim of this
technique is to obtain a three-dimensional molecular structure from a crystal (28). A crystal
consists of atoms arranged in a pattern that repeats in three-dimensional structure (45). The
pattern can consist of an atom or group of atoms, a molecule or group of molecules (45). The
main feature of a crystal is having this pattern repeated for multiple times at regularly spaced
interval with same orientation (45). The good quality of crystal for structure determination is a
rate limiting step (28). Protein crystallization is mainly a trial and error procedure which requires
protein solution to be slowly precipitated out of its solution (46). The presence of impurities,
crystallization nuclei and the unknown factors play major roles in the crystallization of a protein
(46). The general crystallization process is shown in the figure 24. The crystallization of the
protein involves four steps and the first step is to check purity of the protein. If the purity of the
protein is not sufficient based on SDS gel after running ion exchange chromatography, then
further purification steps will be needed (46). The second step involves the protein to be
dissolved in the suitable solvent from which it must be precipitated in crystalline form. The
solvent could be the buffer in which the protein of interest is dialyzed or in extreme examples, a
solvent called 2-methyl-2,4-pentanediol (46). The third step is to bring the solution in a state of
supersaturation and in this step, small aggregates are formed which are known as nuclei that
proceeds crystallization (46). The spontaneous formation of a nuclei requires surface tension
energy and the crystal growth starts to begin when the energy barrier has been overcome (46).
The spontaneous formation of a nuclei is best achieved at higher supersaturation because the
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energy barrier can easily be overcome at higher supersaturation (46). Finally, the fourth step
involved the formation of crystal after the nuclei is formed (46). The level of supersaturation
must be reduced to a lower level to achieve a good crystal growth because high supersaturation
would result in too many nuclei leading to many small crystals (46). The degree of
supersaturation can be changed by changing the temperature and pH (46). The precipitation of
the protein is achieved by increasing the concentration of the protein by adding a salt (salting
out) or polyethyleneglycol (PEG) (46). Some proteins are poorly soluble in the solution but their
solubility increases by the addition of salt (46). By slowly removing the salt, the protein can be
precipitated (46).

Protein Solution

Supersaturation

Nucleation

Crystal Growth

3D Crystal

Figure 24: Crystallization process. Protein solution is supersaturated through vapour diffusion
which proceeds nucleation. From nucleation, crystal growth occurs and 3-D structure of the
crystal is deduced.
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4.8 Supersaturation, Nucleation And Crystal Growth
Crystallization can be divided into two processes and they are nucleation and crystal growth
(47). In order to crystallize a macromolecule, it needs to be in a supersaturated state (44).
Supersaturation is termed as a non-equilibrium condition in which the amount of macromolecule
is in excess of the solubility limit (44). Then, as the protein associates into a regular lattice of a
crystal, equilibrium is established again when the crystal is formed and matures (44). This
phenomenon is explained by using the phase diagram in figure 25 below. This phase diagram is
divided into different regions. The stable (undersaturated) region describes when the
concentration of the macromolecules is lower than the solubility limit. In this region, the process
of crystallization does not occur and the macromolecules are completely dissolved in the
solution. In the metastable region, crystal growth is not visible because nuclei are not formed but
crystal growth could occur if we put a nucleus in that solution. In this region, nuclei will form
into crystals but no nucleation will occur. In the labile region, nuclei will form and crystals may
grow from that nuclei. In the precipitation region, protein precipitates because of high
concentration of both protein and precipitants. If the protein precipitates, then we need to either
fix the concentration of the protein or precipitants or sometimes we need to design a whole new
condition in order to avoid the precipitation region. Crystallization starts with nucleation and the
nucleation of crystal determines many properties of crystalline phase (48). It is known that if
nucleation occurs quickly then many crystals form simultaneously (48). These crystals deplete
the medium of the solute and may end the process of nucleation at the later stages of
crystallization (48). This leads to a formation of crystals of identical sizes (48). If the nucleation
is slow then only a few crystals nucleate at one time (48). Thus, the supersaturation of the
solution decreases slowly and the nucleation of the new crystals continues to happen (48). This
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leads to formation of crystals of varying sizes and forms (48). In this way, we can control the
size, size distribution, polymorphism and others properties of the crystals by controlling
nucleation (48). The process of growth of crystals is well understood than the process of
nucleation (44). Protein crystals grow by the mechanism of dislocation growth and growth by
two-dimensional nucleation (44). It is important to note that both the nucleation and crystal
growth depend on supersaturation (44).

Figure 25: The process of crystallization goes through different region in the phase diagram.
Stable region explains the situation when macromolecules are completely dissolved in the
solution. In the metastable region, nuclei are not formed but crystal growth could occur if we put
a nucleus in that solution. In the labile region, nuclei will form and crystals may grow from the
nuclei. Finally, the precipitation region explains the condition when protein precipitates out of
the solution.
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4.9 Crystallization Techniques
There are many crystallization techniques can be used to grow crystals and they are Batch
crystallization, Liquid-liquid diffusion and vapour diffusion. For our research purpose, we will
concentrate on vapour diffusion technique. This technique is described in figure 26. This
technique can be performed in either the sitting-drop or hanging-drop format and both are
feasible techniques that can be prepared in 24 or 96 well plates (28). In the hanging drop vapour
diffusion, the drops are prepared on a siliconized glass cover slip by mixing different ratios of
protein solution to the different ratios of reservoir solution containing different precipitating
agents, buffers and salts (28). In this method, the droplet contains protein, precipitating agents
and buffer is equilibrated against the reservoir solution containing the same precipitating agent at
higher concentration than the droplet (49). After a certain time period, equilibrium is established
by the evaporation of the volatile component until the vapour pressure of the droplet equals the
vapour pressure of the reservoir (49). The crystals will be formed in the droplet (49). Some
suggested pre-made crystallization screens that may be used are from Microlytic Anatrace
MCSG-1-4 crystal screen HT (1.7mL), Hampton Research Index Solution Set 1 reagents 1-48
HR2-144 and Solution Set 2 reagents 49-96 HR-144. The crystallization incubation period may
range from days to months depending on the screens and conditions that viable crystals can be
grown. In the figure 27, we can see growth of BFO 2294 crystals in a pre-made crystallization
screens and in the figure 28, we can see the growth of BFO 2294 crystals in an expansion plate
grown over a period of three weeks. Once crystals are obtained, they are sent to a facility to
apply X-ray crystallography and data is collected for computational analysis using logarithmic
construction of the 3D structure (29).
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Figure 26: Vapour diffusion. Hanging drop vapour diffusion setup shows coverslip usually
made of glass or plastic. The solution is placed on the coverslip and suspended over reservoir
solution. Figure is taken from the reference (28).

Figure 27: Crystal growth of BFO 2294 in MCSG 2 over seven days. The condition was B4: 1.8
M NaH2PO4/K2HPO4 pH 8.2
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Figure 28: Crystal growth of BFO 2294 in the expansion plate over three weeks. The condition
was 6.25 M of glycerol, 400 μl or 40 M of Tacsimate 7.0 and 106 μl or 11 M of Tacsimate 9.0 at
pH 8.2

4.10 Seeding
Sometimes poor crystal growth pattern results because of the limited formation of nuclei or
spontaneous nucleation occurring at intense level of supersaturation (44). In that case, we can
seed metastable, supersaturated protein solution with the crystals from earlier trials (44). The
seeding techniques can involve two types of seeds and they are seeding with micro crystals and
macro crystals (44). The method of seeding with micro crystals involves the danger of
introducing too many nuclei (44). To overcome this problem, microcrystals could be diluted over
a wide range (44). The solution containing higher concentration of seeds will produce
microcrystals and the solution containing very low concentration of seeds will likely to produce
nothing (44). Another method of seeding is with macrocrystals and the aim should be not to
introduce too many nuclei (44). The technique of seeding is useful for inducing the nucleation,
initiating the growth of crystals and growth at lower level of supersaturation (44).
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4.11 X-Ray Data Collection and Refinement of BFO 2294
After harvesting single crystals, infusing them with cryoprotectants, and freezing them in liquid
nitrogen data may be collected in oscillation mode wherein images are produced by rotating the
crystals and taking regular images of the diffraction pattern through different angles (50). The
resolution of the data starts to increase from the center of the image (50). We need both the
amplitudes of the diffracted X-ray waves and their phase angles in order to calculate the electron
density map of the protein of interest (50). The amplitudes can be measured as the intensities
and positions of the diffraction spots but the phase information is sometimes lost (50). The lost
phase information can be obtained by using the structure of a homologous, also known as
molecular replacement (MR) (50). Another way of obtaining the phase information is to
incorporate the heavy atoms such as Hg, Se into the crystals (50). Molecular replacement (MR)
is a technique used to solve a crystal structure of a known molecular model to solve the unknown
crystal structure of a related molecule (51). The main principle of the MR is very simple. We use
a known model related to the unknown structure we are trying to deduce and also a set of
measured diffraction intensities form the unknown structure using X-ray crystallography (51).
We try all the possible orientations and positions of the unknown crystal model and try to match
predicted diffraction with the observed diffraction (51). Another way of obtaining the phase
information is to incorporate the heavy atoms such as mercury or selenium into the crystals by
soaking (50). Once the correct phase information has been obtained, the new model is built
through the electron density map in order to obtain the structure of the protein (51). The structure
of the crystal BFO 2294 was solved by molecular replacement using the template PDB ID
1WA3. According to Phyre2results , the confidence is100.0 between the template and BFO2294
.showing that the match between them was suggested to have high homologyThe sequence
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identity is 33% between the template and BFO2294 .As we can see from the table 9, the
resolution of this model is about 2.20 Å. The higher resolution data can provide details about
electron density maps (50). At lower resolution, the electron density map is not well defined and
the amino acids side chains cannot be well-modelled (50). A model with a resolution of 2.0 Å
can provide us with active site residues, the binding pattern of an inhibitor, and the information
about hydrogen bonding network (50). One can also measure the unit cell dimensions (50). The
unit cell is the smallest repeating unit making up the crystals (50). The dimensions of the unit
cell are written as three lengths: a, b, and c and three angles: α, β, and γ (50). The crystals are
classified into seven crystal systems according to the shape (50). For the crystal of BFO 2294,
we can see that = ß =  (°) = 900 for the unit cell dimensions. This tells us that this crystal
resembles the cubic crystal system P23 (50). The more diffracted beams (reflections) can be
observed if the unit cell is larger. The intensities of reflections are influenced by the position of
each atom in the crystal. A diffraction analysis requires measuring a large number of reflection
intensities, but some reflections have identical intensity because of the crystals having certain
symmetry. Redundancy is calculated by the number of measured reflections divided by the
number of unique reflections. The average reflection intensity is more accurate when the
redundancy is higher.
Table 9: Data collection and refinement statistics (molecular replacement) of BFO 2294
Space group
Cell dimensions
a = b = c (Å)
= ß =  (°)
Resolution (Å)
Completeness (%)
Redundancy
No. reflections

P23
98.15
900
2.20
100
11.0 (7.4)
179533
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4.12 Multiple Sequence Alignment
Multiple sequence alignment (MSA) of DNA or protein sequence is one of the most commonly
used techniques in sequence analysis (52). Multiple alignments can give us information
regarding the

phylogeny, sequence homology and the structure prediction (52). For this

particular MSA, M-Coffee was used. It is a meta method for assembling MSA by joining the
output of several individual methods into one single MSA (52). M-Coffee is a part of T-Coffee
that uses consistency to estimate a consensus alignment (52). M-Coffee depends on consistency
values and assumes that incorrect alignments are less likely to be consistent than the correct
alignments (52). In figure 29, we showed the MSA of the protein sequence BFO 2294. The
KDPG sequence of other organisms were aligned with the target sequence BFO 2294. The top
portion is colour coded with different colours such as blue, green, yellow and pink. The
sequences coloured in pink correspond to alignment portions with a strong support in the primary
library used by T-Coffee (53). The sequences coloured in other colours such as blue, green and
yellow do not correspond to aligned portions with a strong support in the primary library (53).
Thus, the graphic colored output represent the level of consistency between the final alignment
and the library used by T-Coffee (53). The main score represents the total consistency value and
a value of 100 means strong relationship between the considered alignment and its associated
primary library (53). The higher value of consistency value are proven to show high accuracy
(53). As we can see from the figure 29, each of the sequences were given a consistency value and
the consistency value of each sequence lies in the good region. The residue colour scheme
follows the primary library support for the alignment of the considered residue on a scale
indicating 0 (blue, poorly supported) and 9 (pink, strongly supported) (52). The study suggests
that the residues with a consistency score higher than 5 (yellow, pink) are considered to be
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correctly aligned (52). Thus, this scoring scheme is considered to be the most used method to
identify the highly unreliable residues in a sequence that are aligned in a biologically meaningful
way (52). As we can see, most of the residues of the sequences are coloured in pink and yellow
meaning they are considered to be correctly aligned. If we look at the figure 19, we can see some
of the residues are marked with asterisk signs meaning those residues are exactly the same or
highly conserved in that position. We can see the amino acids glycine, glutamic acid, proline,
phenylalanine and lysine are highly conserved meaning they could be important residues for the
active sites. The residues with semicolons can signify that the residues in that position are very
similar, while dots indicate the residues are less similar. The residues with no sign indicate there
is no similarity between the residues.
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---------------MK----NWKTSAESILT-TGPVVPVIVVKKLEHAVPMAKALVAGGVRVLEVTLRTEC
::.::

.

*.

*..

GLKAIQ-VREQ----RPELCVGAGTVLDRSMFAAVEAAGAQFVVTPGITEDILEAGVDSEIP------LLPG
AADAIRLLRAN----RPDFLA-AGTVLTAEQVVLAKSSGADFVVTPGLNPKIVKLCQDLNFP------ITPG
ADTVIKELSF---LKEKGAIIGAG-VTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVF------YMPG
AHEVFGAVSRWIVEACPEMILGVGSIVDAPTASLYLQSGANFVVGPLTNPDIAKVCNRRLVP------YIPG
GLEALKALR------KSGLLLGAGTVRSPKEAEAALEAGAAFLVSPGLLEEVAALAQARGVP------YLPG
GLAAISAIKKA----VPEAIVGAGTVCTADDFQKAIDAGAQFIVSPGLTPELIEKAKQVKLDGQWQGVFLPG
ALEAIKIMK-E----VPGAVVGAGTVLNAKMLDQAQEAGCEFFVSPGLTADLGKHAVAQKAA------LLPG
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4E38
2V82
1EUN

72 AVEAIRLLRQA----QPEMLIGAGTILNGEQALAAKEAGATFVVSPGFNPNTVRACQEIGID------IVPG
45 WEQSIPAIVD---AYGDKALIGAGTVLKPEQVDALARMGCQLIVTPNIHSEVIRRAVGYGMT------VCPG
53 AVDAIRAIAKE----VPEAIVGAGTVLNPQQLAEVTEAGAQFAISPGLTEPLLKAATEGTIP------LIPG
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144

ISTPSEIM-GYALGYRRFKLFPAEISGGVAAIKAFGGPFG-DIRFCPTGGVNPA--NVRNYMALPNVMCV-G
VNNPMAIEIALEMGISAVKFFPAEASGGVKMIKALLGPYA-QLQIMPTGGIGLH--NIRDYLAIPNIVAC-G
VMTPTELVKAMKLGHTILKLFPGEVVG-PQFVKAMKGPFP-NVKFVPTGGVNL--DNVCEWFK-AGVLAVGV
CGSVSEVGYAQELGCDICKVFPGDVLG-PGFVKALKAPMP-WSQVMVTGGVKPKEANLKAWFD-AGATCVGM
VLTPTEVERALALGLSALKFFPAEPFQGVRVLRAYAEVFP-EVRFLPTGGIKEE--HLPHYAALPNLLAV-G
VATASEVMIAAQAGITQLKCFPASAIGGAKLLKAWSGPFP-DIQFCPTGGISKD--NYKEYLGLPNVICA-G
VANAADVMLGLDLGLDRFKFFPAENIGGLPALKSMASVFR-QVRFCPTGGITPA--SAPKYLENPSILCV-G
VNNPSTVEAALEMGLTTLKFFPAEASGGISMVKSLVGPYG-DIRLMPTGGITPS--NIDNYLAIPQVLAC-G
CATATEAFTALEAGAQALKIFPSSAFG-PQYIKALKAVLPSDIAVFAVGGVTPE--NLAQWID-AGCAGAGL
ISTVSELMLGMDYGLKEFKFFPAEANGGVKALQAIAGPFS-QVRFCPTGGISPA--NYRDYLALKSVLCI-G
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Figure 29: MSA generated by T-Coffee. The sequences coloured in pink correspond to
alignment portions with a strong support in the primary library used by T-Coffee but the
sequences coloured in other colours such as blue, green and yellow do not correspond to aligned
portions with a strong support in the primary library.

4.13 Structure of KDPG Aldolase
The enzyme 2-keto-3-deoxy-6 phosphogluconate (KDPG) aldolase is an important enzyme in the
Entner-Doudoroff pathway which breaks down KDPG through class I Schiff-base mechanism
(54). This enzyme plays an important role in the Entner-Doudoroff pathway of bacteria where it
catalyzes reversible cleavage of KDPG to pyruvate and glyceraldehyde-3-phosphate (55). The
structure of this enzyme has been determined to be a monomer containing 226 amino acids
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residues according to research paper. The research paper shows that this enzyme has tertiary
folding and the subunit contains eight α-helices and eight β-strands (56) (57). This is also known
as α/β-barrel structure or TIM barrel structure. The α/β-barrel structure is situated on the Nterminal side and the carboxylic side contains the active site (54). The subunit contains a
phosphate ion which is bound to the aldolase binding site (58). KDPG aldolase is a class I
aldolase because KDPG aldolase involves the Schiff base formation between carbonyl substrate
and lysine residue in the active site of this enzyme (55). The active site of BFO 2294 contains
zwitterionic pair of Glu-49 and Lys-141 according to the research paper (55). The residue lysine
is involved in the formation of Schiff base which is coordinated by phosphate ion and two water
molecules (54) (58). The first water molecule acts as a shuttle between the glutamic acid and the
substrate and the second water molecule is the product of the dehydration of the of the
carbinolamine leading to the formation of the Schiff base (58). It also functions as a nucleophile
during the hydrolysis of the enzyme product complex which leads to the release of the pyruvate
molecule (58). The structure of BFO 2294 is shown in figure 30.
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Figure 30: Structure of BFO 2294. The structure showing active residues lysine (blue) and
glutamate (green).

4.14 Mechanism of KDPG Aldolase
Based on the different research paper on KDPG aldolase structure and mechanism, we came up
with mechanism of BFO 2294 which is shown in figure 31. The enzyme BFO 2294 catalyzes the
reversible cleavage of 2-keto-3deoxy-6-phosphogluconate (KDPG) into pyruvate and Dglyceraldehyde-3-phosphate by aldol cleavage (55) (58). In the first step, a proton transfer occurs
between the zwitterionic pair Glu-49/Lys-141 in the active site and it activates lysine to
participate as a nucleophile in the reaction (55). In the second step, glutamate is involved in the
base catalysis in the carbon-carbon cleavage (55). The residue lysine-141 acts as a nucleophile
and attacks the carbonyl group of 2-keto-3deoxy-6-phosphogluconate that forms a protonated
carbinolamine intermediate or Schiff base (55) (58). This intermediate is stabilized by the
hydrogen bonding with the residues (lysine and glutamate) in the active site (55). Then, the three
carbon molecule glyceraldehyde 3-phosphate is cleaved off by base catalysis using water
molecule and Glu-49 (58) (55). The other product pyruvate is generated by the nucleophilic
attack of water on the Schiff base to form a ketone and also aromatic interaction with Phe-143
makes sure that the stereospecific addition is involved in the reverse process (55).
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Figure 31: Mechanism of action of KDPG aldolase. In the first step, proton transfer occurs
between the zwitterionic pair Glu-49/Lys-141 in the active site and it activates lysine to act as
nucleophile. In the second step, glutamate is involved in the base catalysis in the carbon-carbon
cleavage. Figure is taken from the reference (59).
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5. CONCLUSION
The research presented herein was centred on glycosaminoglycans (GAGs) degradation by the
dental pathogen T. forsythia. Using bioinformatics, GAGs degradations pathway was established
which explains how different enzymes secreted from the bacterium Tannerella forsythia
degrades one of the GAGs called chondroitin sulfate A. The two putative enzymes: BFO 2291
(chondroitin AC lyase) and BFO 2294 (KDPG aldolase) were the main focus of the research.
Based on the bioinformatics and enzyme kinetics, it was found that the chondroitin sulfate A was
the substrate for the enzyme BFO 2291. It was shown that there is a noticeable activity of this
enzyme when acted upon chondroitin sulfate A but it requires further testing using better
reproducibility and correct temperature condition. The research also showed the optimum pH at
which BFO 2291 had the maximum activity. The pH at which the enzyme had the maximum
activity was phosphate buffer at pH 6.5. The other enzyme BFO 2294 had noticeable activity
towards the substrate KDPG using coupled enzymatic assay. The enzyme BFO 2294 was
successfully crystallized and its structure and mechanism of action was found using various
research journals. Doing research into characterizing the following gene products BFO 2291 and
BFO 2294 can guide us in understanding the degradation of periodontal tissues during
periodontitis. In the future, crystallization BFO 2291 could lead to a better understanding of the
mechanism of this enzyme during depolymerisation of chondroitin sulfate A. Another part of this
research was to identify the products of enzyme-substrate reaction and it could be another part of
this research where the products can be identified. If one looks at the GAGs degradations
pathway, one can see that there are other different enzymes involved in degradations of
chondroitin sulfate A. In future, other researchers can work towards solving the whole pathway
and can have a better understanding on how these enzymes work together during pathogenesis.
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This may lead to the development of some drugs that can halt the progression of periodontitis by
deactivating certain enzymes in the GAGs degradations pathway.
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APPENDICES
Appendix I

Figure 32: pET 21b+ plasmid. The figure shows different components of the plasmid. It also
shows different restriction enzyme cut sites.
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Appendix II

Figure 33: Interpro results of BFO 2291. The figure tells us the protein family BFO 2291
belongs to and the major domains of BFO 2291.
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Appendix III

Chondroitin sulfate A

y = 0.00260x + 0.644
R² = 0.698
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Figure 34: Substrate specificity. Chondroitin sulfate A shows a small increase in absorbance.
The concentration of the substrate was 1 mg/mL, enzyme concentration (BFO 2291) was 50
μg/mL, the buffer was 50 mM of sodium phosphate at pH 6.5.
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y = -0.00410x + 0.137
R² = 0.678

Chondroitin sulfate B
0.14
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Figure 35: Substrate specificity. Chondroitin sulfate B shows decrease in absorbance. The
concentration of the substrate was 1 mg/mL, enzyme concentration (BFO 2291) was 50 μg/mL,
the buffer was 50 mM of sodium phosphate at pH 6.5.
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Figure 36: Substrate specificity. Shark chondroitin sulfate also shows small increase in
absorbance as well due to the presence of chondroitin sulfate A. The concentration of the
substrates was 1 mg/mL, enzyme concentration (BFO 2291) was 50 μg/mL, the buffer was 50
mM of sodium phosphate at pH 6.5.
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Figure 37: Enzyme kinetics for BFO 2294. This shows the relationship between the increase in
concentration of the KDPG and the amount of product being formed. The buffer used was 50
mM Hepes at pH 7.0, 500 mM stock concentration of the substrate 2-keto-3-deoxy-6phosphogluconate (KDPG), the enzyme concentration (BFO 2294) was 50 μg/mL, and L-lactic
dehydrogenase from rabbit muscle: Type II, ammonium sulfate suspension, 800-1,200 units/mg
protein
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